A Phase IC Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Cognitive Outcomes of BI 409306 in Patients with Mild-to-Moderate Schizophrenia

DOI: 10.1007/s40120-017-0085-5

Keywords: BI 409306, Cognitive outcome, Phosphodiesterase inhibitor, PDE9A, Pharmacokinetics, Phase I, Safety, Schizophrenia, Tolerability

Full-Text   Cite this paper   Add to My Lib

Abstract:

Study desig

Full-Text